BioNotebook: 3 IPOs launch, 2 file; AMAG 4Q earnings; Repros FDA update
This article was originally published in Scrip
Executive Summary
On their first day as public companies, Egalet broke even, Eleven Biotherapeutics gained 8.5% and Revance Therapeutics closed 67.8% above its initial public offering price on 6 February.
You may also be interested in...
Does Deal With Roche Signal Eleven's Doomed Fate?
Eleven Biotherapeutics Inc. more than doubled in value in early trading on June 13 before closing up 27.8% at $2.39 per share after the company said it licensed EBI-031, its lead development program, to Roche – a move that could signal Eleven's intention to wind down the eye disease-focused company.
Sanofi Clinches Key Phase III Immunology Win With Rilzabrutinib
Sanofi’s BTK inhibitor – one of two from its 2021 Principia buy – passed a Phase III test in immune thrombocytopenia as the company focuses on Dupixent-like blockbusters going forward.
Ipsen Expands Its Rare Neurological Disease Pipeline With Skyhawk Deal
Deal Snapshot: Ipsen committed up to $1.8bn in upfront and milestone fees to develop novel treatments for rare neurological diseases with Skyhawk’s RNA-targeting small molecule platform.